EUVIMEDEUVIMED entdecken
Crossref

Melatonin–vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat

Youssef Y Helmi, Niklas Papenkordt, Georg Rennar, Florence Gbahou, Ahmed K El-Hady, Nedjma Labani, Karin Schmidtkunz, Stefan Boettcher, Ralf Jockers, Mohammad Abdel-Halim, Manfred Jung, Darius P Zlotos

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Youssef Y Helmi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Cairo, Egypt. Hauptthemen laut MEDLINE: Melatonin, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung, • Fondation pour la Recherche Médicale (FRM - France), • La Ligue Contre le Cancer (France).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticancer drug conjugates are an emerging approach for future cancer treatment. Here, we report a series of hybrid ligands merging the neurohormone melatonin with the approved histone deacetylase (HDAC) inhibitor vorinostat, using melatonin's amide side chain ( 3a–e ), its indolic nitrogen ( 5a–d ), and its ether oxygen ( 7a–d ) as attachment points. Several hybrid ligands showed higher potency thanvorinostat in both HDAC inhibition and cellular assays on different cultured cancer cell lines. In the most potent HDAC1 and HDAC6 inhibitors, 3e, 5c , and 7c , the hydroxamic acid moiety of vorinostat is linked to melatonin through a hexamethylene spacer. Hybrid ligands 5c and 7c were also found to be potent growth inhibitors of MCF‐7, PC‐3M‐Luc, and HL‐60 cancer cell lines. As these compounds showed only weak agonist activity at melatonin MT 1 receptors, the findings indicate that their anticancer actions are driven by HDAC inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninAntineoplastic AgentsNeoplasmsVorinostatHistone DeacetylasesLigandsStructure-Activity RelationshipHistone Deacetylase InhibitorsHydroxamic AcidsCell Line, TumorCell ProliferationHistone Deacetylase 1Histone Deacetylase 6

Stichwörter der Autor:innen

anticancer drug conjugatesmelatoninvorinostat

Substanzen

VorinostatHistone DeacetylasesMelatoninLigandsHistone Deacetylase InhibitorsAntineoplastic AgentsHydroxamic AcidsHistone Deacetylase 1Histone Deacetylase 6

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Cairo, Egypt.
  • Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
  • Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France.
  • Department of Organic and Pharmaceutical Chemistry, School of Life and Medical Sciences, University of Hertfordshire hosted by Global Academic Foundation, New Administrative Capitol, Cairo, Egypt.
  • Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbruecken, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung
  • • Fondation pour la Recherche Médicale (FRM - France)
  • • La Ligue Contre le Cancer (France)
  • • Centre National de la Recherche Scientifique (CNRS - France)
  • Deutscher Akademischer Austauschdienst
  • China Scholarship Council, Huazhong University of Science and Technology, (Wuhan - China)

Zitieren

APA

Helmi, Y. Y., Papenkordt, N., Rennar, G., Gbahou, F., El-Hady, A. K., Labani, N., Schmidtkunz, K., Boettcher, S., Jockers, R., Abdel-Halim, M., Jung, M., & Zlotos, D. P. (2023). Melatonin–vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300149

Vancouver

Helmi YY, Papenkordt N, Rennar G, Gbahou F, El-Hady AK, Labani N, et al. Melatonin–vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300149

BibTeX
@article{Helmi2023,
  author = {Helmi, Youssef Y and Papenkordt, Niklas and Rennar, Georg and Gbahou, Florence and El-Hady, Ahmed K and Labani, Nedjma and Schmidtkunz, Karin and Boettcher, Stefan and Jockers, Ralf and Abdel-Halim, Mohammad and Jung, Manfred and Zlotos, Darius P},
  title = {Melatonin–vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300149}
}
Kostenlos starten →